NEO - NeoGenomics stock pops on launch of next-gen sequencing tests
2023-03-13 07:47:03 ET
- NeoGenomics ( NASDAQ: NEO ) said it launched multiple tests expanding its next-generation sequencing (NGS).
- The commercially available test now include, Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms.
- "With our new, easy to interpret reports, even faster turn-around times, and low sample requirements, these new tests offer clinicians industry leading testing options to support the management of their patients with cancer, across various stages and types of disease," said NeoGenomics CEO Chris Smith.
- The company added that it is also introducing two software resources, NeoAccess and NeoSeek.
- NeoAccess is a test requisitioning tool that includes clinical decision support, up-front patient benefits check and prior authorization assistance. Meanwhile, NeoSeek allows clinicians to mine their previous testing data to identify patients who may be biomarker eligible for a new therapy or clinical study, according to NeoGenomics.
- NEO +2.03% to $17.11 premarket March 13
For further details see:
NeoGenomics stock pops on launch of next-gen sequencing tests